Is it time for tailored treatment of rectal cancer? from prescribing by consensus to prescribing by numbers

Radiotherapy and Oncology

Volumn 102, Issue 1, 2012, Pages 1-3

  Valentini, Vincenzo ^a   Lambin, Philippe ^b   Myerson, Robert J ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CONSENSUS; HUMAN; METASTASIS; MONOTHERAPY; NOMOGRAM; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; RECTUM CARCINOMA; REVIEW; TREATMENT OUTCOME;

EID: 84455202271     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.12.001     Document Type: Editorial

References (27)

1. R. Sauer, H. Becker, and W. Hoyhenberger For the German rectal cancer study group. Pre-operative versus post-operative chemoradiotherapy for rectal cancer New Engl J Med 351 2004 1731 1740
2. J.P. Gérard, T. Conroy, and F. Bonnetain Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 J Clin Oncol 24 2006 4620 4625
3. J.F. Bosset, L. Collette, G. Calais, L. Mineur, P. Maingon, and L. Radosevic-Jelic EORTC radiotherapy group trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
4. V. Valentini, R.G. van Stiphout, and G. Lammering Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials J Clin Oncol 29 2011 3163 3172
5. W. van Gijn, C.A. Marijnen, and I.D. Nagtegaal Dutch colorectal cancer group preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer 12-year follow-up of the multicentre randomised controlled TME trial Lancet Oncol 12 2011 575 582
6. D. Sebag-Montefiore, R.J. Stephens, and R. Steele Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial Lancet 373 2009 811 820
7. V. Valentini, C. Aristei, and B. Glimelius Multidisciplinary rectal cancer management: 2nd European rectal cancer consensus conference (EURECA-CC2) Radiother Oncol 92 2009 148 163
8. L. Phlman, M. Bohe, and B. Cedermark The Swedish rectal cancer registry Br J Surg 94 2007 1285 1292
9. C. Aschele, L. Cionini, and S. Lonardi Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial J Clin Oncol 29 2011 2773 2780 [e-publication]
10. J.P. Gérard, D. Azria, and S. Gourgou-Bourgade Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2 J Clin Oncol 28 2010 1638 1644
11. C. Rodel, H. Becker, and R. Fietkau Preoperative chemoradiotherapy, postoperative chemotherapy with 5-fluorouracil, oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: first results of the German CAO/ARO/AIO-04 randomized phase III trial J Clin Oncol 29 2011 [suppl; abstr LBA3505]
12. M.S. Roh, G.A. Yothers, and M.J. O'Connell The impact of capecitabine, oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04 J Clin Oncol 29 2011 [suppl; abstr 3503]
13. G. Quasar Collaborative, R. Gray, and J. Barnwell Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study Lancet 370 2007 2020 2029
14. I.D. Nagtegaal, and P. Quirke What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26 2008 303 312
15. V. Valentini, and B. Glimelius Rectal cancer radiotherapy: towards European consensus Acta Oncol 49 2010 1206 1216
16. M. Maas, P.J. Nelemans, and V. Valentini Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data Lancet Oncol 11 2010 835 844
17. D. Mak, D.L. Joon, and M. Chao The use of PET in assessing tumor response after neoadjuvant chemoradiation for rectal cancer Radiother Oncol 97 2010 205 211
18. V. Valentini, R. Beets-Tan, and J.M. Borras Evidence and research in rectal cancer Radiother Oncol 87 2008 449 474
19. D. Sebag-Montefiore, K. Bujko, and V. Valentini Rectal cancer multidisciplinary management: evidences and future landscape Radiother Oncol 92 2009 145 147
20. K. Haustermans, A. Debucquoy, and M. Lambrecht The ESTRO Breur lecture 2010: toward a tailored patient approach in rectal cancer Radiother Oncol 100 2011 15 21
21. P. Manchon-Walsh, J.M. Borras, and J.A. Espinas Catalonian rectal cancer group. Assessing the effectiveness of a guideline recommendation for pre-operative radiochemotherapy in rectal cancer Radiother Oncol 99 2011 142 147
22. P. Lambin, S.F. Petit, and H.J. Aerts The ESTRO Breur lecture 2009. From population to voxel-based radiotherapy exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer Radiother Oncol 96 2010 145 152 [e-publication]
23. R.G. van Stiphout, G. Lammering, and J. Buijsen Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging Radiother Oncol 98 2011 126 133
24. M.H. Janssen, M.C. Ollers, and R.G. van Stiphout Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings Radiother Oncol 94 2010 151 155
25. J. Buijsen, J. van den Bogaard, and M.H. Janssen FDG-PET provides the best correlation with the tumor specimen compared to MRI and CT in rectal cancer Radiother Oncol 98 2011 270 276
26. J. van den Bogaard, M.H. Janssen, and G. Janssens Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer Radiother Oncol 99 2011 137 141
27. J. Gaedcke, M. Grade, and K. Jung KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy Radiother Oncol 94 2010 76 81